Reemergence of PML in Natalizumab-Treated Patients - New Cases, Same Concerns

被引：68
作者：
Major, Eugene O. [1 ]
机构：
[1] NINDS, Lab Mol Med & Neurosci, Bethesda, MD 20892 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2009年 / 361卷 / 11期
关键词：
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ANTIBODY NATALIZUMAB; CELLS;
D O I：
10.1056/NEJMp0906248
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1041 / 1043
页数：3
相关论文
共 42 条
[21]   Assessment of JC Virus DNA in Blood and Urine from Natalizumab-Treated Patients [J].
Rudick, Richard A. ;
O'Connor, Paul W. ;
Polman, Chris H. ;
Goodman, Andrew D. ;
Ray, Soma S. ;
Griffith, Nancy M. ;
Jurgensen, Stephanie A. ;
Gorelik, Leonid ;
Forrestal, Fiona ;
Sandrock, Alfred W. ;
Goelz, Susan E. .
ANNALS OF NEUROLOGY, 2010, 68 (03) :304-310
[22]   Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCVA® DxSelect™ antibody assay [J].
Campagnolo, Denise ;
Dong, Qunming ;
Lee, Lily ;
Ho, Pei-Ran ;
Amarante, Diogo ;
Koendgen, Harold .
JOURNAL OF NEUROVIROLOGY, 2016, 22 (06) :880-881
[23]   JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients [J].
Delbue, Serena ;
Elia, Francesca ;
Carloni, Camilla ;
Pecchenini, Valentina ;
Franciotta, Diego ;
Gastaldi, Matteo ;
Colombo, Elena ;
Signorini, Lucia ;
Carluccio, Silvia ;
Bellizzi, Anna ;
Bergamaschi, Roberto ;
Ferrante, Pasquale .
JOURNAL OF NEUROVIROLOGY, 2015, 21 (06) :645-652
[24]   Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance [J].
Kagstrom, Stina ;
Falt, Anna ;
Berglund, Anders ;
Piehl, Fredrik ;
Olsson, Tomas ;
Lycke, Jan .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 50
[25]   Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients [J].
Fine, Andrew J. ;
Sorbello, Alfred ;
Kortepeter, Cindy ;
Scarazzini, Linda .
CLINICAL INFECTIOUS DISEASES, 2013, 57 (06) :849-852
[26]   Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate [J].
Scarpazza, Cristina ;
Signori, Alessio ;
Cosottini, Mirco ;
Sormani, Maria Pia ;
Gerevini, Simonetta ;
Capra, Ruggero .
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (10) :1227-1236
[27]   Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy [J].
Serana, Federico ;
Chiarini, Marco ;
Sottini, Alessandra ;
Bertoli, Diego ;
Giustini, Viviana ;
Tessitore, Marion Vaglio ;
Caimi, Luigi ;
Capra, Ruggero ;
Imberti, Luisa .
JOURNAL OF NEUROIMMUNOLOGY, 2014, 277 (1-2) :6-12
[28]   The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis [J].
Robier, C. ;
Amouzadeh-Ghadikolai, O. ;
Bregant, C. ;
Diez, J. ;
Melinz, K. ;
Quehenberger, F. ;
Quasthoff, S. .
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 (05) :469-474
[29]   The use of cytokine signature patterns: separating drug naive, interferon and natalizumab-treated multiple sclerosis patients [J].
O'Connell, Kara E. ;
Mok, Tzehow ;
Sweeney, Brian ;
Ryan, Aisling M. ;
Dev, Kumlesh K. .
AUTOIMMUNITY, 2014, 47 (08) :505-511
[30]   JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients [J].
Mancuso, Roberta ;
Saresella, Marina ;
Hernis, Ambra ;
Marventano, Ivana ;
Ricci, Cristian ;
Agostini, Simone ;
Rovaris, Marco ;
Caputo, Domenico ;
Clerici, Mario .
JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
12345